Previous 10 | Next 10 |
2024-04-05 16:14:43 ET More on AstraZeneca, Daiichi Sankyo What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript AstraZeneca Imfinzi im...
2024-04-05 07:43:40 ET More on AstraZeneca What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript FDA accepts Daiichi Sankyo-AstraZeneca...
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful ...
2024-04-04 08:20:35 ET More on CureVac BV CureVac: No Momentum In Sight Seeking Alpha’s Quant Rating on CureVac BV Historical earnings data for CureVac BV Financial information for CureVac BV Read the full article on Seeking Alpha For f...
2024-04-02 08:16:01 ET AstraZeneca ( NASDAQ: AZN ) and Daiichi Sankyo’s ( OTCPK:DSNKY ) ( OTCPK:DSKYF ) biologics license application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the U.S. for patients with previously treated metastatic HR-posit...
Application based on results from the TROPION-Breast01 Phase III trial Additional BLA under review in the US for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for patients with advanced nonsquamous non-small cell lung cancer AstraZeneca and Daiichi Sankyo&...
Application based on results from the TROPION-Breast01 phase 3 trial Additional BLA under review in the U.S. for Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan for patients with advanced nonsquamous non-small cell lung cancer Daiichi Sankyo (TSE: 4568) and AstraZenec...
2024-04-01 14:26:55 ET More on AstraZeneca What AstraZeneca Is Getting Through The Acquisition Of Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript Japan approves AstraZeneca-Sanofi drug...
Approval of first-in-class, oral, Factor D inhibitor based on results from pivotal ALPHA Phase III trial VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal ...
2024-04-01 06:08:19 ET Summary Cytokinetics' stock has seen much buyout speculation in recent months, with companies like Eli Lilly, Novartis, Johnson & Johnson, Amgen, and AstraZeneca being potential suitors. The company's Phase 3 study for aficamten, a treatment for heart di...
News, Short Squeeze, Breakout and More Instantly...
AstraZeneca PLC Company Name:
AZN Stock Symbol:
NYSE Market:
2024-06-29 22:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
First immunotherapy regimen before and after surgery to extend survival in bladder cancer Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) in combination with chemotherapy demonstrated a statistically sign...
2024-06-20 08:46:01 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group – This year’s 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) has now come and gone, but not without increasing hope for...